Literature DB >> 6691923

Effect of pure erythropoietin on DNA-synthesis by human marrow day 15 erythroid burst forming units in short-term liquid culture.

E N Dessypris, S B Krantz.   

Abstract

The effect of pure erythropoietin (EP) on human marrow day 15 burst-forming units-erythroid (BFU-E) was studied using a short-term liquid culture system containing 30% human serum. Non-adherent marrow cells were cultured in liquid medium for 0-48 h and then the number of BFU-E was assayed by the use of the plasma clot method. The addition of 1 U/ml of EP into the liquid culture medium resulted in maintenance of the number of BFU-E assayed after 24-48 h of incubation. The number of BFU-E recovered after 24-48 h culture was directly proportional to the concentration of EP present in the liquid medium. In addition, the proliferative status of BFU-E before and after exposure to EP was studied by 3H-thymidine and hydroxyurea suicide. It was found that EP doubles the percentage of BFU-E in DNA synthesis after 24-48 h of incubation in the liquid medium. This effect of EP on DNA synthesis by bone marrow day 15 BFU-E is detectable as early as 6 h after the onset of incubation and at EP concentrations as low as 0.2 U/ml of medium, a concentration present in the serum of moderately anaemic patients. The human marrow day 15 BFU-E is an EP-responsive cell and pure EP can induce it into DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691923     DOI: 10.1111/j.1365-2141.1984.tb03957.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin.

Authors:  C A Sieff; S G Emerson; A Mufson; T G Gesner; D G Nathan
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

2.  Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties.

Authors:  D C Linch; J M Lipton; D G Nathan
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

3.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

4.  Interleukin 3 promotes erythroid burst formation in "serum-free" cultures without detectable erythropoietin.

Authors:  J W Goodman; E A Hall; K L Miller; S G Shinpock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Purification of erythroid progenitor cells and characterization of erythropoietin receptors.

Authors:  S B Krantz; S T Sawyer; K I Sawada
Journal:  Br J Cancer Suppl       Date:  1988-12

6.  Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea.

Authors:  R Galanello; G Stamatoyannopoulos; T Papayannopoulou
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

7.  Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells.

Authors:  K Muta; S B Krantz; M C Bondurant; A Wickrema
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

8.  EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts.

Authors:  Jing Fang; Madhu Menon; William Kapelle; Olga Bogacheva; Oleg Bogachev; Estelle Houde; Sarah Browne; Pradeep Sathyanarayana; Don M Wojchowski
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113

9.  Recombinant human erythropoietin alters gene expression and stimulates proliferation of MCF-7 breast cancer cells.

Authors:  Nina Trost; Tina Stepisnik; Sabina Berne; Anja Pucer; Toni Petan; Radovan Komel; Natasa Debeljak
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.